Paolo A. Ascierto, Full Professor of Oncology at the University of Naples Federico II, Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Cancer Institute IRCCS Pascale Foundation, shared a post on LinkedIn:
“mRNA cancer vaccines and immunotherapy: a new era in oncology.
Oncology research is rapidly advancing toward highly targeted immune-based treatments. More than 200 clinical trials worldwide are currently evaluating therapeutic mRNA vaccines designed to train the immune system to identify and eliminate malignant cells.
The most mature evidence comes from melanoma, where personalized mRNA vaccines combined with immune checkpoint inhibitors have been shown to lower the risk of relapse and significantly improve disease-free survival. Encouraging phase II data are also emerging in lung and pancreatic cancers, suggesting that vaccine-guided immune activation after surgery may prevent tumor recurrence.
This approach represents a major step forward in precision oncology, integrating immunology, molecular profiling and artificial intelligence to optimize patient-specific treatment strategies.
We sincerely thank Roberta Pasero for her clear and high-quality scientific reporting on this important breakthrough.”
More posts featuring Paolo A. Ascierto.
